CME Presentations
Nasal Polyps
Presentations
Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps: ENT, Allergist, and Patient Partnerships to Enhance Care and QoL
Speakers: Noam Cohen, MD, PhD, Professor of Otorhinolaryngology – Head and Neck SurgeryJohn Bosso, MD, Clinical Profressor, Division of Rhinology Duration: 60 minutes
Presented on: October 21, 2022
Speakers
Noam Cohen, MD, PhD
Noam Cohen, MD, PhD
Professor of Otorhinolaryngology – Head and Neck Surgery
John Bosso, MD
John Bosso, MD
Clinical Profressor, Division of Rhinology
John V. Bosso, MD, serves as medical director of the Aspirin Exacerbated Respiratory Disease (AERD or Samter’s triad) Center and director of the OTO-Allergy Clinic at Penn Medicine in Philadelphia. He is one of the country’s most experienced AERD super-specialists with over 30 years of expertise in managing this challenging condition. Dr Bosso was one of the first allergy/immunology fellows to learn the techniques of aspirin desensitization and has subsequently successfully desensitized over 1000 AERD patients. His current research focuses on potential causes, molecular mechanisms, and treatments of AERD. Dr Bosso has spoken at national otorhinolaryngology meetings and served on AERD panels. In addition, he is a proud supporter of the Samter’s Society, a support group for AERD sufferers.
CME Information
Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps: ENT, Allergist, and Patient Partnerships to Enhance Care and QoL
ACKNOWLEDGEMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and SanofiLIVE RELEASE DATE
Friday, October 21 from 11:00 AM-12:00 PM ET.TARGET AUDIENCE
The target audiences for the proposed HCP activity are specialty NPs and PAs, Allergists, Immunologists, ORLs/ENTs, Specialist NPs and PAsSTATEMENT OF NEED/PROGRAM OVERVIEW
Many patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who fail first-line treatment or are ineligible for systemic corticosteroids undergo functional endoscopic sinus surgery (FESS), which has high associated costs, a likelihood of recurrence, and potential complications. However, new evidence supports the efficacy, tolerability, impact on quality of life, and place in treatment of targeted biologics approved for the management of CRSwNP.
Join an expert panel of clinicians to review the underlying pathophysiology of CRSwNP and the heavy disease burden patients with recurrent nasal polyps experience. Approvals of monoclonal antibodies targeting T2 inflammation offer additional options for patients. Panelists will clarify the place of FESS and biologic agents in the treatment of CRSwNP refractory to standard treatments, of recurring nasal polyps after surgery, and in people who cannot receive systemic steroids. Enhanced partnerships between allergists and ear, nose, and throat specialists, along with greater inclusion of each patient’s voice in care, can ensure more patient-centered and effective treatment of CRSwNP.
Do you have patients with nasal polyps who could benefit from related education on the latest treatment strategies and advances? Direct your patients to MedLive.com to access the activity, “Breathe, Finally: Practical, Proactive Approaches to Receive Personalized Care for Your Nasal Polyps.”EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Describe the burden of disease faced by patients with recurrent NPs or those who are not eligible for systemic corticosteroids
- Summarize data documenting the efficacy and safety of new T2 inflammation targeted biologic agents, including impacts on QoL and bothersome symptoms, in people with refractory NPs and recurrent NPs after FESS, as well as those ineligible for systemic corticosteroids
- Recognize the place of biologic agents targeting T2 inflammation in the management of patients with NPs
- Describe strategies to engage patients with NPs in shared-decision making to enhance access to patient-centered care and improve patient satisfaction and QoL
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Dr. John Bosso
Clinical Professor
Division of Rhinology
Department of Otorhinolaryngology: Head and Neck Surgery
Perelman School of Medicine at The University of PennsylvaniaResearch Grant: Cumberland Pharma, Optinose Advisory Boards: Novartis, Sanofi/Regeneron, GSK Dr. Noam A. Cohen, MD, PhD
Professor of Otorhinolaryngology – Head and Neck Surgery
Perelman School of Medicine at The University of PennsylvaniaOwner/Co-Owner Founder/Co-Founder: 4 Sinuses LLC (consulting company)
Consulting Fee: AstraZeneca, GlaxoSmithKline, OysterPoint, Sanofi/Regeneron
Stock Option Holder: OysterPoint
Royalty: GeneOne Life Sciences
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Carole Drexel Nothing to disclose Lauren Sinclair Nothing to disclose Eve Wilson Nothing to disclose Caroline Laurendeau Nothing to disclose Jack Vielbig- Patient with sinus and Nasal polyps Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.Moving Toward a Targeted Approach for Nasal Polyps
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:- Summarize the disease burden experienced by patients with NPs
- List the limitations of traditional interventions for NPs, including oral or nasal steroids, antibiotics, and surgery
- Explain the rationale for locally and immunologically targeted approaches to NP management
- Summarize the efficacy and safety of new and emerging therapies with new mechanisms of action and/or modes of administration for people with NPs
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the Asthma and Allergy Foundation of America (AAFA).
This activity is supported by an independent medical education grant from OptiNose US Inc, Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.LIVE CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ENDURING CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.DATE OF RELEASE/EXPIRATION
Live Activity
Friday, July 30, 2021 from 3:00 – 4:00pm ETEnduring Material
The enduring material will be available from July 30, 2021 to July 30, 2022.TARGET AUDIENCE
The intended audience for this activity are otorhinolaryngologists (ORLs), allergists, primary care physicians, advanced practitioners (nurse practitioners and physician assistants), and nurses.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:Name of Faculty or Presenter Reported Financial Relationship John V. Bosso, MD
Clinical Professor
Division of Rhinology
Deptartment of Otorhinolaryngology: Head and Neck Surgery
University of Pennsylvania
Perelman School of MedicineConsulting Fees (e.g., advisory boards): GSK, Novartis, Sanofi-Regeneron, AstraZeneca
Contracted Research: OptiNose US IncSanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of AmericaNothing to disclose Zachary M. Soler, MD, MSc
Associate Professor of Otolaryngology Head Neck Surgery
Medical University of South CarolinaConsulting Fees (e.g., advisory boards): GSK, Lyra, Novartis, OptiNose US Inc, Sinusonic
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Carole Drexel
Medical Director
PlatformQ Health Education, LLCNone
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@ImmunologyLive.com.